Bioventus Inc
NASDAQ:BVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bioventus Inc
NASDAQ:BVS
|
US |
|
Beigene Ltd
SSE:688235
|
KY |
|
JACCS Co Ltd
TSE:8584
|
JP |
|
Accrete Inc
TSE:4395
|
JP |
|
Bank Mestika Dharma Tbk PT
IDX:BBMD
|
ID |
|
Altron Ltd
F:RY7A
|
ZA |
|
zSpace, Inc.
NASDAQ:ZSPC
|
US |
|
S
|
Sobal Corp
TSE:2186
|
JP |
|
Ride On Express Holdings Co Ltd
TSE:6082
|
JP |
|
Arista Networks Inc
NYSE:ANET
|
US |
|
Midea Group Co Ltd
SZSE:000333
|
CN |
|
Firefinch Ltd
ASX:FFX
|
AU |
|
Stella-Jones Inc
TSX:SJ
|
CA |
|
A
|
Answear.Com SA
WSE:ANR
|
PL |
|
O
|
OpenWork Inc
TSE:5139
|
JP |
|
S
|
Sincere Watch (Hong Kong) Ltd
HKEX:444
|
HK |
|
Taiwan Taffeta Fabric Co Ltd
TWSE:1454
|
TW |
|
X
|
XiAn Bright Laser Technologies Co Ltd
SSE:688333
|
CN |
|
P
|
Peric Special Gases Co Ltd
SSE:688146
|
CN |
|
N
|
New World Resources Ltd
ASX:NWC
|
AU |
|
RNI Negocios Imobiliarios SA
BOVESPA:RDNI3
|
BR |
|
Embracer Group AB
STO:EMBRAC B
|
SE |
|
T
|
Tianjin Tianbao Energy Co Ltd
HKEX:1671
|
CN |
|
R
|
Resilux NV
LSE:0FSN
|
BE |
Bioventus Inc
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
Results: Revenue of $158 million in Q4, up 3% reported and 10% organic; adjusted EBITDA of $37 million, up $8 million (30%), and adjusted EBITDA margin of 23%, up 490 bps year‑over‑year.
Cash Flow: Q4 cash from operations was approximately $38 million (a quarterly record); full year cash from operations was nearly $75 million and management expects $82–$87 million in 2026.
2026 Guide: Net sales guidance of $600–$610 million; adjusted EPS guidance of $0.73–$0.77; management expects an adjusted EBITDA margin of approximately 20% in 2026.
Growth Priorities: Management will invest ~$13 million incremental in 2026 to accelerate four growth drivers (PNS, PRP, Ultrasonics, international), with PNS receiving the largest share.
Pilot Learnings: Pilot launches for PNS and PRP gave positive physician and patient feedback; company reaffirmed a minimum 200 bps revenue contribution from PNS+PRP in 2026.
Balance Sheet: Cash on hand $51 million, outstanding debt $294 million, net leverage below 2.5x at quarter end and expected to be well below 2x by end of 2026.
Segment dynamics: Pain Treatments accelerated (Q4 +15%), Surgical Solutions modestly up (Q4 +3%) with capital timing noise, Restorative Therapies down 26% reported due to an Advanced Rehabilitation divestiture (10% organic growth ex‑divestiture).
Risks/Seasonality: Q1 2026 expected to be the weakest quarter (one fewer selling day and HA distributor inventory rebalancing); FX had an unfavorable impact (~$1 million in Q4, >$3 million for the year).
